Press Releases

Eloxx Pharmaceuticals Receives a US$6 Million Investment from KIP and DCS to Advance a Novel Disease-Modifying Therapy Targeting Genetic Diseases Including Cystic Fibrosis
June 30, 2017
Mitoconix Bio Raises $20 Million in Series A Funding to Develop Neurodegenerative Disease Therapies
June 27, 2017
RM Global Partners Completes $30 Million First Closing of New Israel-Based Biopharma Fund
May 20, 2017
BiomX Raises $24 Million in Series A Funding to Develop Microbiome Therapeutics
May 15, 2017
Read all Press Releases
Equity investment in Elastagen’s Series B and Strategic Collaboration with Elastagen
Confidential
Advised AMOREPACIFIC
on the foregoing transaction
Series B Financing
$15 milion
Advised KAHR Medical
on the foregoing transaction
Series B Preferred Stock Financing
$7.5 milion
Advised Checkpoint Surgical
on the foregoing transaction
Equity Financing
$22.4 milion
Advised MediBeacon
on the foregoing transaction
Global Licensing Agreement Cardiovascular Device Platform
Confidential
Advised Distal Access
on the foregoing transaction
Sale of Pharmacuetical Business Assets to Handok
$55 million
Advised Amore Pacific
on the foregoing transaction
Series D Private Equity Placement
$20 Million equity
Advised Obalon
on the foregoing transaction
Formation of AmorePacific Ventures
$70 million
Advised Amore Pacific
on the foregoing transaction
Private Placement (both series C and series D)
$41.6 Million
Advised Neothetics
on the foregoing transaction
Series D Financing
$21 million
Advised Micrus
on the foregoing transaction
Acquisition of Avantec Vascular
$160 million
Advised Goodman
on the foregoing transaction
Acquisition and Financing of Spinout of Magellan Product Line & Related Assets from Medtronic
$10 million (growth financing)
Advised Arteriocyte Medical System
on the foregoing transaction
Equity Financing
$11 million
Advised Anterios
on the foregoing transaction
Convertible Note Financing and Licensing of Rights to Travelan to Paladin
Up to $117 million
Advised Immuron
on the foregoing transaction
Equity Financing
$12.5 million
Advised IBI
on the foregoing transaction
Series C Financing and Strategic Collaboration
$20 million
Advised Vascular Therapies
on the foregoing transaction
Spin-off and Financing
$8 million
Advised MiCardia
on the foregoing transaction

Industry News

Since 1992, we have advised entrepreneurs, management teams, and investors to build and grow value, over the entire life cycles of their businesses. We specialize in life sciences, operating globally.

 

RM Global - Team

Diverse Team

The senior professional team at RM Global brings over 100 years of combined operational, financial, transactional and strategic experience in life science.

 

 

Broad Experience

Broad Experience

Our client base ranges broadly from start-ups to R&D companies, growth stage companies, and leading multinationals, with over $3 billion in M&A and strategic transactions and over $300 million in start-up funding raised to date.

world map

Global Reach

Unique network of leading corporations, funds, institutional and strategic investors, family offices, industry experts and management teams across the Americas, Asia, Europe and Israel enable us to provide our full scope of services worldwide.